Funding: InSightec closes $30.9 million Series C round

Mon, 12/10/2012 - 6:00pm
Mass Device

InSightec completes $30.9 million Series C financing round, led by GE Healthcare and other investors. Lands CE Marked approval for its ExAblate Neuro in the treatment of Parkinson's disease.

InSightec picked off $30.9 million in a Series C financing round, led by a $27.6 million investment from GE Healthcare and $3.3 million by other investors, the company said.

In addition, the Israeli-based ultrasound maker also named VP & general manager of the MRI business James Davis as new CEO and Tom Gentile as chairman of board. Gentile most recently was
president & CEO of GE Healthcare.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.